Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth

$EPRXPress releaseJul 13, 2026, 4:05 PM ETRead the release

Eupraxia Pharmaceuticals strengthened its executive team by appointing Dr. Jeff Millard as EVP of Technical Operations and shifting Dr. Alex Therien to lead R&D as EVP. The leadership overhaul is designed to support the company's transition to late-stage development, specifically ahead of the Q4 2026 interim data release for the Phase 1b/2 RESOLVE trial of EP-104GI.

Key figures

Phase: Phase 1b/2
Interim data release: Q4 2026
Csos resignation date: July 10, 2026

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.